莫小兰,雷会雯,何艳玲,陈冬莹,陈孝,陈杰,杨岫岩,李嘉丽
MO Xiaolan,LEI Huiwen,HE Yanling,CHEN Dongying,CHEN Xiao,CHEN Jie,YANG Xiuyan,LI Jiali

• 1:广州市妇女儿童医疗中心药学部
• 2:中山大学附属第一医院药学部
• 3:中山大学附属第一医院风湿科
• 4:中山大学药学院

摘要(Abstract)：

目的探讨相关基因多态性和非遗传因素对甲氨蝶呤治疗强直性脊柱炎的疗效和毒性的影响,为个体化用药提供依据。方法选择105例于2009年12月~2015年1月在某院风湿科就诊的强直性脊柱炎患者。采用限制性片段长度多态性聚合酶链式反应法检测6个单核苷酸基因多态性位点,包括RFC1 G80A、MDR1 C3435T、GGH C-401T、FPGS(rs1544105)G>A、MTHFR C677T和MTHFR A1298C。采用χ~2检验、非参数检验、回归分析等方法检验上述基因及非遗传因素与甲氨蝶呤疗效及毒性间的相关性。结果年龄对强直性脊柱炎功能指数、疾病活动指数(BASFIb、BASDAIb)有显著影响(P=0.027,P=0.004),年龄越大,疗效越差(r=-0.216,r=-0.276)。MTHFR A1298C与总疗效有显著相关性(P=0.017),纯合型的患者更容易发生治疗失败。MDR1 C3435T纯合型对BASFIb有影响,纯合型患者躯体功能恢复更差(P=0.046)。各基因型与不良反应间的相关性差异无统计学意义。结论 MTHFR A1298C、MDR1 C3435T及年龄显著影响疗效,需注意个体化给药。暂未发现甲氨蝶呤不良反应的风险基因。
OBJECTIVE To determine the correlation between gene polymorphisms,non-genetic factors and efficacy and toxicity of methotrexate therapy in patients with ankylosing spondylitis for individual administration. METHODS A number of 105 patients with ankylosing spondylitis were recruited,who were treated in department of rheumatology between Dec. 2009 and Jan. 2015. Genotypes of RFC1 G80 A,MDR1 C3435 T,GGH C-401 T,FPGS( rs1544105) G > A,MTHFR C677 T and MTHFR A1298 C were detected by PCRRFLP method. The correlation between genetic factors and non-genetic factors and efficacy and toxicity of methotrexate were analyzed by using chi-square test,non-parametric test and regression analysis,etc. RESULTS BASFIb、BASDAIb were impacted by age( P =0.027,P = 0.004). The older the patient,the lower the response( r =-0.216,r =-0.276). Total response was affected significantly by MTHFR A1298C( P = 0.017). Patients carried with MTHFR 1298 CC genotype were more likely experienced low efficacy. BASFIb was affected by MDR1 C3435 T. Patients carried with TT genotype were harder to get good response. No association was found between genetic polymorphisms and toxicity. CONCLUSION The efficacy of methotrexate is impacted by MTHFR A1298 C,MDR1 C3435 T and age. More attention should be paid to those patients for better efficacy by individual administration. No risk genotype is found to correlate with toxicity of methotrexate.

关键词(KeyWords)： 甲氨蝶呤;强直性脊柱炎;单核苷酸基因多态性
methotrexate;ankylosing spondylitis;single nucleotide polymorphism

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81603203);; 广东省医学科学技术研究基金(A2016400);; 广东省临床用药研究基金(2015FS10)

作者(Author): 莫小兰,雷会雯,何艳玲,陈冬莹,陈孝,陈杰,杨岫岩,李嘉丽
MO Xiaolan,LEI Huiwen,HE Yanling,CHEN Dongying,CHEN Xiao,CHEN Jie,YANG Xiuyan,LI Jiali

参考文献(References)：

• [1]蒋明,David Y,林孝义,等.中华风湿病学[M].北京:华夏出版社,2004:1002-1005.
• [2]Ma H J,Yin Q F,Hu F P,et al.Different clinical features in patients with ankylosing spondylitis from southern and northern China[J].Int J Rheum Dis,2012,15(2):154-162.
• [3]中华医学会风湿病学分会.强直性脊柱炎诊断及治疗指南[J].中华风湿病学杂,2010,14(8):557-559.
• [4]Strand V,Cohen S,Schiff M,et al.Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate.Leflunomide Rheumatoid Arthritis Investigators Group[J].Arch Intern Med,1999,159(21):2542-2550.
• [5]Kodidela S,Suresh C P,Dubashi B.Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia:why still at the bench level[J].Eur J Clin Pharmacol,2014,70(3):253-260.
• [6]Tarnowski M,Paradowska-Gorycka A,Dabrowska-Zamojcin E,et al.The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy[J].Expert Opin Drug Metab Toxicol,2016,12(1):41-55.
• [7]Zochling J,van der Heijde D,Burgos-Vargas R,et al.ASAS/EULAR recommendations for the management of ankylosing spondylitis[J].Ann Rheum Dis,2006,65(4):442-452.
• [8]莫小兰,何艳玲,雷会雯,等.风湿性疾病患者MDR1、RFC1、GGH、FPGS和MTHFR基因型研究[J].今日药学,2016,26(7):462-467.
• [9]广东省药学会.风湿免疫疾病超药品说明书用药专家共识(之三)——强直性脊柱炎[J].今日药学,2017,27(1):1-8.
• [10]Kenna T J,Hanson A,Costello M E,et al.Functional Genomics and Its Bench-to-Bedside Translation Pertaining to the Identified Susceptibility Alleles and Loci in Ankylosing Spondylitis[J].Curr Rheumatol Rep,2016,18(10):63.
• [11]王育凯.亚甲基四氢叶酸还原酶和胸苷酸合成酶基因多态性的检测及其意义研究[D].汕头:汕头大学,2008.
• [12]Dervieux T,Wessels J A,Kremer J M,et al.Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis[J].Pharmacogenet Genomics,2012,22(1):1-9.
• [13]Fransen J,Kooloos W M,Wessels J A,et al.Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure[J].Pharmacogenomics,2012,13(9):1087-1094.
• [14]Malik F,Ranganathan P.Methotrexate pharmacogenetics in rheumatoid arthritis:a status report[J].Pharmacogenomics,2013,14(3):305-314.
• [15]Wessels J A,de Vries-Bouwstra J K,Heijmans B T,et al.Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes[J].Arthritis Rheum,2006,54(4):1087-1095.
• [16]Urano W,Taniguchi A,Yamanaka H,et al.Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis,as evidenced by single locus and haplotype analyses[J].Pharmacogenetics,2002,12(3):183-190.
• [17]Kato T,Hamada A,Mori S,et al.Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis[J].Drug Metab Pharmacokinet,2012,27(2):192-199.
• [18]Taraborelli M,Andreoli L,Archetti S,et al.Methylenetetrahydrofolate reductase polymorphisms and methotrexate:no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients[J].Clin Exp Rheumatol,2009,27(3):499-502.
• [19]Soukup T,Dosedel M,Pavek P,et al.The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients[J].Rheumatol Int,2015,35(7):1149-1161.
• [20]de Rotte M C,Bulatovic M,Heijstek M W,et al.ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis[J].J Rheumatol,2012,39(10):2032-2040.
• [21]Kooloos W M,Wessels J A,van der Straaten T,et al.Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis[J].Pharmacogenomics,2010,11(2):163-175.
• [22]Song G G,Bae S C,Lee Y H.Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis:a meta-analysis[J].Clin Rheumatol,2014,33(12):1715-1724.
• [23]Qiu Q,Huang J,Lin Y,et al.Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis:A systematic review and meta-analysis[J].Medicine(Baltimore),2017,96(11):e6337.
• [24]Chen Y,Zou K,Sun J,et al.Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis?A systematic review and meta-analysis[J].Pharmacogenomics,2017,18(2):175-195.